|1.||Meltzer, Herbert Y: 3 articles (10/2008 - 04/2005)|
|2.||Raaska, K: 3 articles (08/2002 - 11/2000)|
|3.||Neuvonen, P J: 3 articles (08/2002 - 11/2000)|
|4.||Barr, Alasdair M: 2 articles (12/2015 - 08/2010)|
|5.||Mulsant, Benoit H: 2 articles (06/2015 - 01/2012)|
|6.||Pollock, Bruce G: 2 articles (06/2015 - 01/2012)|
|7.||Rajji, Tarek K: 2 articles (06/2015 - 01/2012)|
|8.||Flanagan, Robert J: 2 articles (05/2013 - 02/2004)|
|9.||Dai, Jin: 2 articles (10/2008 - 10/2007)|
|10.||Li, Zhu: 2 articles (10/2008 - 10/2007)|
|1.||Schizophrenia (Dementia Praecox)
04/01/2015 - "The aims of the study were to explore the association of clozapine+ norclozapine serum concentration and other factors with subjective side-effects in schizophrenia patients. "
07/01/2007 - "To study the relationship between age, gender, cigarette smoking and plasma concentrations of clozapine (CLZ) and its metabolite, norclozapine (NCLZ) in Chinese patients with schizophrenia. "
12/01/2015 - "Cognition and Plasma Ratio of Clozapine to N-desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia."
06/01/2015 - "Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine."
11/01/2012 - "To develop a combined population pharmacokinetic model (PPK) to assess the magnitude and variability of exposure to both clozapine and its primary metabolite norclozapine in Chinese patients with refractory schizophrenia via sparse sampling with a focus on the effects of covariates on the pharmacokinetic parameters. "
|2.||Drug Toxicity (Drug Safety)
05/01/1997 - "The aim of this open study was to determine a more rational therapeutic approach for psychotic patients treated with clozapine for several months, using measurement of plasma and red blood cell levels (P, RBC) of clozapine (cloza) and N-desmethylclozapine (descloza), the major metabolite of clozapine, which has been reported to be less active but more toxic (agranulocytosis) than clozapine itself. "
11/01/1997 - "N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia."
03/01/1994 - "Bone marrow from patients with acute clozapine-induced agranulocytosis was not more sensitive to clozapine or N-desmethylclozapine than bone marrow from normal donors. "
11/01/1997 - "We reviewed the charts of 58 patients with treatment-refractory schizophrenia who were receiving clozapine, to determine if the drug's active metabolite, N-desmethylclozapine, is a biologic marker for impending clozapine-induced granulocytopenia and agranulocytosis. "
|4.||Parkinson Disease (Parkinson's Disease)
03/01/2004 - "The goal of the present study was to determine the effects of clozapine (Cloz) and its metabolites norclozapine (Norcloz) and clozapine-N-oxide (Cloz-N-oxide) on the 5-HT(2) receptor system on the levels of protein and gene expression in in vitro systems of primary cortical cells of the rat and human hippocampal SHS5Y5 neuroblastoma cells. "
|5.||Antipsychotic Agents (Antipsychotics)
|6.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|7.||Levodopa (L Dopa)
|8.||Influenza Vaccines (FluMist)
|10.||Fibroblast Growth Factor 7